141 related articles for article (PubMed ID: 33309262)
1. SATB2 is not a reliable diagnostic marker for distinguishing between oral osteosarcoma and fibro-osseous lesions of the jaws.
Grad-Akrish S; Rachmiel A; Ben-Izhak O
Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 May; 131(5):572-581. PubMed ID: 33309262
[TBL] [Abstract][Full Text] [Related]
2. Special AT-rich sequence-binding protein 2 (SATB2) expression is sensitive but may not be specific for osteosarcoma as compared with other high-grade primary bone sarcomas.
Davis JL; Horvai AE
Histopathology; 2016 Jul; 69(1):84-90. PubMed ID: 26644288
[TBL] [Abstract][Full Text] [Related]
3. The utility of SATB2 immunohistochemical expression in distinguishing between osteosarcomas and their malignant bone tumor mimickers, such as Ewing sarcomas and chondrosarcomas.
Machado I; Navarro S; Picci P; Llombart-Bosch A
Pathol Res Pract; 2016 Sep; 212(9):811-6. PubMed ID: 27465835
[TBL] [Abstract][Full Text] [Related]
4. SATB2 is frequently expressed in ossifying and non-ossifying peripheral oral fibroma of the gingival region but not in reactive fibromatous lesions from other intraoral sites.
Baněčková M; Agaimy A
Ann Diagn Pathol; 2020 Jun; 46():151510. PubMed ID: 32252013
[TBL] [Abstract][Full Text] [Related]
5. SOX9 and SATB2 immunohistochemistry cannot reliably distinguish between osteosarcoma and chondrosarcoma on biopsy material.
Sharma AE; Pytel P; Cipriani NA
Hum Pathol; 2022 Mar; 121():56-64. PubMed ID: 35016891
[TBL] [Abstract][Full Text] [Related]
6. SATB2 and MDM2 Immunoexpression and Diagnostic Role in Primary Osteosarcomas of the Jaw.
Owosho AA; Ladeji AM; Adesina OM; Adebiyi KE; Olajide MA; Okunade T; Palmer J; Kehinde T; Vos JA; Cole G; Summersgill KF
Dent J (Basel); 2021 Dec; 10(1):. PubMed ID: 35049602
[TBL] [Abstract][Full Text] [Related]
7. SATB2 is a novel marker of osteoblastic differentiation in bone and soft tissue tumours.
Conner JR; Hornick JL
Histopathology; 2013 Jul; 63(1):36-49. PubMed ID: 23701429
[TBL] [Abstract][Full Text] [Related]
8. [Value of MDM2, CDK4 and SATB2 immunohistochemistry in histologic diagnosis of low-grade osteosarcoma].
Chen CY; Zhang HZ; Jiang ZM; Zhou J; Chen J; Liu L
Zhonghua Bing Li Xue Za Zhi; 2016 Jun; 45(6):387-92. PubMed ID: 27256046
[TBL] [Abstract][Full Text] [Related]
9. SATB2 Immunopositivity in Spindle Cell (Sarcomatoid) Squamous Cell Carcinoma: A Potential Pitfall in Diagnosis.
Sasidharan A; Kakkar A; Thakar A; Deo SVS
Appl Immunohistochem Mol Morphol; 2022 Mar; 30(3):184-189. PubMed ID: 35262524
[TBL] [Abstract][Full Text] [Related]
10. SATB2 Expression Is Sensitive but Not Specific for Osteosarcomatous Components of Gynecologic Tract Carcinosarcomas: A Clinicopathologic Study of 60 Cases.
Sangoi AR; Kshirsagar M; Horvai AE; Roma AA
Int J Gynecol Pathol; 2017 Mar; 36(2):140-145. PubMed ID: 27294605
[TBL] [Abstract][Full Text] [Related]
11. [Significance of SATB2 in the pathologic diagnosis of osteosarcoma].
Li M; Cai YP; Lu KY; Chen Y; Zhu X; Yin Y; Tang J
Zhonghua Bing Li Xue Za Zhi; 2016 Sep; 45(9):631-5. PubMed ID: 27646893
[TBL] [Abstract][Full Text] [Related]
12. Psammomatoid Ossifying Fibroma Is Defined by SATB2 Rearrangement.
Cleven AHG; Szuhai K; van IJzendoorn DGP; Groen E; Baelde H; Schreuder WH; Briaire-de Bruijn IH; van der Meeren SW; Kleijwegt MC; Furth WR; Kroon HM; Suurmeijer AJH; Savci-Heijink DC; Baumhoer D; Bovée JVMG
Mod Pathol; 2023 Jan; 36(1):100013. PubMed ID: 36788065
[TBL] [Abstract][Full Text] [Related]
13. Expression of SATB2 in primary cutaneous sarcomatoid neoplasms: a potential diagnostic pitfall.
Szczepanski JM; Siddiqui J; Patel RM; Harms PW; Hrycaj SM; Chan MP
Pathology; 2023 Apr; 55(3):350-354. PubMed ID: 36732203
[TBL] [Abstract][Full Text] [Related]
14. SATB2 Expression in Human Tumors: A Tissue Microarray Study on More Than 15 000 Tumors.
Dum D; Kromm D; Lennartz M; De Wispelaere N; Büscheck F; Luebke AM; Burandt E; Menz A; Kluth M; Hube-Magg C; Hinsch A; Höflmayer D; Weidemann S; Fraune C; Möller K; Lebok P; Sauter G; Simon R; Uhlig R; Wilczak W; Minner S; Krech R; Bernreuther C; Marx A; Steurer S; Jacobsen F; Clauditz T; Krech T
Arch Pathol Lab Med; 2023 Apr; 147(4):451-464. PubMed ID: 35917493
[TBL] [Abstract][Full Text] [Related]
15. Histomorphometric Analysis of Pre- and Post-Denosumab-Treated Giant Cell Tumor of Bone.
Ud Din N; Umer M; Park YK
Int J Surg Pathol; 2020 Dec; 28(8):859-867. PubMed ID: 32429739
[No Abstract] [Full Text] [Related]
16. SATB2 Immunoexpression in Peripheral Ossifying Fibroma and Peripheral Odontogenic Fibroma.
Shahrabi-Farahani S; Pencarinha DM; Anderson M
Head Neck Pathol; 2022 Jun; 16(2):339-343. PubMed ID: 34224081
[TBL] [Abstract][Full Text] [Related]
17. Role of SATB2 in distinguishing the site of origin in glandular lesions of the bladder/urinary tract.
Giannico GA; Gown AM; Epstein JI; Revetta F; Bishop JA
Hum Pathol; 2017 Sep; 67():152-159. PubMed ID: 28711650
[TBL] [Abstract][Full Text] [Related]
18. Metformin reduces SATB2-mediated osteosarcoma stem cell-like phenotype and tumor growth via inhibition of N-cadherin/NF-kB signaling.
Xu HY; Fang W; Huang ZW; Lu JC; Wang YQ; Tang QL; Song GH; Kang Y; Zhu XJ; Zou CY; Yang HL; Shen JN; Wang J
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4516-4528. PubMed ID: 29131265
[TBL] [Abstract][Full Text] [Related]
19. SATB2 is a novel marker of osteoblastic differentiation and colorectal adenocarcinoma.
Ordóñez NG
Adv Anat Pathol; 2014 Jan; 21(1):63-7. PubMed ID: 24316906
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of radiological and clinicopathological features of craniofacial fibro-osseous lesions].
Yang XD; Xu G; Song LH; Zhu H; Liu X; Li FH; Peng SK; Ma ZY; Zhou H
Zhonghua Bing Li Xue Za Zhi; 2020 Feb; 49(2):122-128. PubMed ID: 32074723
[No Abstract] [Full Text] [Related]
[Next] [New Search]
